The pharmaceutical giant's revenue jumped 21 per cent last year despite growing troubles over its presence in China, where it ...

In a report released today, James Gordon from J.P. Morgan maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target ...

By Pushkala Aripaka and Maggie Fick (Reuters) -AstraZeneca shares rose on Thursday after the drugmaker said it could face a ...

AstraZeneca said the taxes related to two cancer drugs, Imfinzi and Imjudo, and that it was continuing to co-operate with ...

AstraZeneca could face a fine of up to $4.5 million in China over suspected unpaid taxes related to the import of two of its ...

Drugmaker AstraZeneca has warned it could face a fine in China over possible unpaid import taxes, as it revealed strong sales ...

Chief executive Emma Walmsley said ministers must work with the sector to boost investment amid growing concerns about doing ...

New growth and inflation projections are due to be unveiled later alongside the Bank of England’s latest interest rates ...

European shares hovered near a record high on Thursday, buoyed by a raft of upbeat earnings, including drugmaker AstraZeneca, ...

AstraZeneca overcame a drop in sales in China and the arrest of its top executive in the country to deliver an 18 per cent increase in revenues in the final quarter 2024. The London-listed company ...

AstraZeneca Plc reported better-than-expected profit and sales in the fourth quarter and forecast further gains as the UK drugmaker’s blockbuster cancer drugs offset weakened China sales.